Collectively, these findings suggest a model whereby histone methyltransferases that promote gene expression undergo frequent loss of function and/or expression in cancer (i.e., KMT2D), while those that typically repress gene expression often are overexpressed or characterized by a gain of function (i.e., EZH2). This evidence concerns the gene PRDM9 and cancer.